Entrepreneurs Develop Drugs Against Alzheimer’s
New mechanism of action developed
Düsseldorf/Jülich, 22 September 2017 – The development of novel therapies and drugs for the treatment of diseases such as Alzheimer’s is the focus of a spin-off company from Forschungszentrum Jülich and Heinrich Heine University Düsseldorf. “Priavoid GmbH”, the company founded by Prof. Dieter Willbold and his team, took up its work a few days ago. The scientists have developed a candidate drug for the treatment of Alzheimer’s. This drug has now passed the preclinical tests. The scientists have been supported by Forschungszentrum Jülich, the Helmholtz Validation Fund, the university of Düsseldorf, and the Volkswagen Foundation.